Spevatamig (PT886)
PreclinicalSmall molecule
Spevatamig (PT886) is one of 7 small molecule programs targeting Gastric or Gastroesophageal Junction Adenocarcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Gastric or Gastroesophageal Junction Adenocarcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPreclinical
Gemzar
Johnson & JohnsonPreclinical
Abraxane
Bristol-Myers SquibbPreclinical
Keytruda
Merck & Co.Preclinical
FOLFOX
AstraZenecaPreclinical
Folfirinox
PPhanes Therapeutics
Preclinical
Spevatamig (PT886)
PPhanes Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric or Gastroesophageal Junction Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Spevatamig (PT886). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPhanes Therapeutics